Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metoclopramide + trimebutine
- Development stage
- Unknown
- Lead developer
- Sohag University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
metoclopramide + trimebutine is a combination of two prokinetic agents used to enhance gastrointestinal motility and improve surgical outcomes. Metoclopramide acts as a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, which promotes gastric emptying and increases lower esophageal sphincter tone. Trimebutine is a non-selective enkephalinergic agonist that binds to mu, delta, and kappa opioid receptors, exerting a regulatory effect on the digestive tract by stimulating or inhibiting motility depending on the baseline state. This combination was studied by Sohag University in patients undergoing emergency intestinal anastomosis to assess its efficacy in reducing postoperative ileus, anastomotic leakage, and the formation of postoperative adhesions.
- Brand names
- Gastreg
- Other names
- metoclopramidetrimebutine
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)HTR3A (5-hydroxytryptamine receptor 3A)LTCC (Voltage-gated calcium channel (L-type))Kir (Inward-rectifier potassium channels)MOR (Mu opioid receptor)DRD2 (Dopamine D2 Receptor)CaV3 (Caveolin-3)
Beyond the preview
Go deeper on metoclopramide + trimebutine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metoclopramide + trimebutine.